Kristian Reich Selected Research

Psoriasis (Pustulosis Palmaris et Plantaris)

10/2022	Maintenance of response in moderate-to-severe psoriasis after withdrawal of the interleukin (IL)-17A and IL-17F nanobody sonelokimab: is there a role for IL-17F in disease reoccurrence?
6/2022	Efficacy of guselkumab versus secukinumab in subpopulations of patients with moderate-to-severe plaque psoriasis: results from the ECLIPSE study.
5/2022	Network meta-analysis comparing the efficacy of biologic treatments for achieving complete resolution of nail psoriasis.
5/2022	Efficacy and Safety of Ixekizumab Versus Adalimumab in Biologic-naïve Patients With Active Psoriatic Arthritis and Moderate-to-severe Psoriasis: 52-week Results From the Randomized SPIRIT-H2H Trial.
4/2022	Long-term Safety of Secukinumab Over Five Years in Patients with Moderate-to-severe Plaque Psoriasis, Psoriatic Arthritis and Ankylosing Spondylitis: Update on Integrated Pooled Clinical Trial and Post-marketing Surveillance Data.
3/2022	Safety of Brodalumab in Plaque Psoriasis: Integrated Pooled Data from Five Clinical Trials.
2/2022	Early Response is Associated With Stable Long-Term Response in Psoriasis Patients Receiving Ixekizumab or Ustekinumab.
1/2022	Quality-of-Life Outcomes, Effectiveness and Tolerability of Apremilast in Patients with Plaque Psoriasis and Routine German Dermatology Care: Results from LAPIS-PSO.
1/2022	Secukinumab demonstrates high and sustained efficacy in nail psoriasis: post hoc analysis from phase III trials in patients with psoriatic arthritis.
1/2022	International eDelphi Study to Reach Consensus on the Methotrexate Dosing Regimen in Patients With Psoriasis.

For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Kristian Reich Research Topics

Disease

120	Psoriasis (Pustulosis Palmaris et Plantaris) 10/2022 - 01/2002
15	Infections 03/2022 - 12/2008
14	Atopic Dermatitis (Atopic Eczema) 01/2022 - 04/2002
12	Neoplasms (Cancer) 03/2022 - 09/2002
8	Psoriatic Arthritis 05/2022 - 06/2007
7	Inflammatory Bowel Diseases (Inflammatory Bowel Disease) 08/2021 - 09/2008
5	Inflammation (Inflammations) 01/2021 - 06/2004
5	Melanoma (Melanoma, Malignant) 07/2012 - 09/2002
4	Pruritus (Itching) 01/2022 - 07/2011
4	Necrosis 02/2014 - 02/2003
4	Hypersensitivity (Allergy) 07/2011 - 02/2003
3	Nasopharyngitis 01/2022 - 01/2021
3	Pain (Aches) 01/2022 - 01/2017
3	Eczema 01/2022 - 02/2003
3	Respiratory Tract Infections (Respiratory Tract Infection) 01/2021 - 01/2021
3	Crohn Disease (Crohn's Disease) 01/2021 - 03/2017
3	Candidiasis (Moniliasis) 01/2021 - 07/2016
3	Hypertension (High Blood Pressure) 01/2021 - 07/2012
3	Skin Neoplasms (Skin Cancer) 02/2020 - 12/2008
3	Rheumatoid Arthritis 02/2014 - 07/2003
2	Body Weight (Weight, Body) 06/2022 - 10/2010
2	Ankylosing Spondylitis 04/2022 - 01/2019
2	Cardiovascular Diseases (Cardiovascular Disease) 03/2022 - 01/2019
2	Obesity 01/2022 - 07/2015
2	Headache (Headaches) 01/2022 - 01/2021
2	Oral Candidiasis (Thrush) 01/2021 - 01/2021
2	Ulcerative Colitis 02/2020 - 03/2017
2	Injection Site Reaction 01/2019 - 02/2018
2	Herpes Labialis (Fever Blister) 01/2016 - 01/2008
2	Arthritis (Polyarthritis) 07/2015 - 05/2006
2	Drug-Related Side Effects and Adverse Reactions 12/2008 - 07/2007
2	Allergic Contact Dermatitis 12/2003 - 02/2003
1	Non-Radiographic Axial Spondyloarthritis 04/2022
1	Human Influenza (Influenza) 01/2022
1	Wounds and Injuries (Trauma) 01/2022
1	Herpes Simplex 01/2022

Drug/Important Bio-Agent (IBA)

19	Interleukin-17 (Interleukin 17)IBA 10/2022 - 02/2014
19	Monoclonal AntibodiesIBA 01/2022 - 10/2005
18	ixekizumabIBA 05/2022 - 01/2012
17	secukinumabIBA 06/2022 - 07/2014
15	Ustekinumab (CNTO 1275)FDA Link 03/2022 - 05/2008
14	InterleukinsIBA 10/2022 - 01/2002
14	Adalimumab (Humira)FDA Link 05/2022 - 09/2008
14	Biological ProductsIBA 05/2022 - 05/2008
13	Etanercept (Enbrel)FDA Link 02/2018 - 09/2008
13	Infliximab (Remicade)FDA Link 10/2011 - 10/2005
12	guselkumabIBA 06/2022 - 07/2015
12	Immunoglobulin A (IgA)IBA 06/2022 - 01/2019
11	Tumor Necrosis Factor-alpha (Tumor Necrosis Factor)IBA 08/2018 - 01/2002
10	CytokinesIBA 01/2021 - 01/2002
9	FumaratesIBA 01/2022 - 03/2007
7	Interleukin-23 (Interleukin 23)IBA 01/2021 - 02/2009
7	Pharmaceutical PreparationsIBA 09/2020 - 09/2008
6	Methotrexate (Mexate)FDA LinkGeneric 01/2022 - 03/2009
6	Adrenal Cortex Hormones (Corticosteroids)IBA 01/2022 - 10/2011
6	AntibodiesIBA 01/2019 - 09/2008
5	Interleukin-12 (IL 12)IBA 01/2022 - 05/2008
4	Prostaglandins AIBA 05/2022 - 07/2009
4	Tumor Necrosis Factor InhibitorsIBA 01/2021 - 03/2008
4	bimekizumabIBA 01/2021 - 01/2021
4	Proteins (Proteins, Gene)FDA Link 07/2012 - 09/2002
4	Interleukin-16 (Interleukin 16)IBA 01/2011 - 04/2002
3	Cyclosporine (Ciclosporin)FDA LinkGeneric 01/2022 - 10/2011
3	baricitinibIBA 01/2022 - 12/2020
3	TabletsIBA 01/2022 - 03/2007
3	upadacitinibIBA 01/2022 - 01/2020
3	ChemokinesIBA 01/2021 - 07/2003
3	Immunoglobulin E (IgE)IBA 01/2019 - 07/2011
3	calcipotriene (calcipotriol)FDA LinkGeneric 06/2017 - 08/2014
3	Dimethyl FumarateIBA 07/2009 - 03/2007
3	Peroxisome Proliferator-Activated Receptors (PPAR)IBA 02/2007 - 09/2002
2	sonelokimabIBA 10/2022 - 01/2021
2	Janus KinasesIBA 01/2022 - 01/2021
2	apremilastIBA 01/2022 - 07/2015
2	Janus Kinase InhibitorsIBA 06/2021 - 01/2021
2	Filaggrin ProteinsIBA 01/2021 - 01/2011
2	Interleukin-13IBA 01/2021 - 01/2019
2	Janus Kinase 1IBA 12/2020 - 01/2020
2	omega-Chloroacetophenone (Mace)IBA 02/2020 - 03/2012
2	AerosolsIBA 06/2017 - 01/2017
2	betamethasone-17,21-dipropionate (betamethasone dipropionate)FDA LinkGeneric 06/2017 - 01/2017
2	Acyclovir (Aciclovir)FDA LinkGeneric 01/2016 - 01/2008
2	Omalizumab (Xolair)FDA Link 07/2013 - 07/2011
2	AllergensIBA 07/2011 - 02/2003
2	AutoantibodiesIBA 07/2011 - 02/2007
2	Glutathione Transferase (Glutathione S-Transferase)IBA 01/2011 - 01/2007
2	efalizumab (Raptiva)FDA Link 01/2010 - 06/2006
2	PPAR gammaIBA 02/2007 - 09/2002
2	LigandsIBA 06/2004 - 09/2002
2	PPAR alphaIBA 06/2004 - 09/2002
1	brodalumabIBA 03/2022
1	Anthralin (Dithranol)IBA 01/2022
1	HLA Antigens (Human Leukocyte Antigens)IBA 01/2022
1	GlucocorticoidsIBA 01/2022
1	HLA-C Antigens (HLA-C)IBA 01/2022

Therapy/Procedure

47	Therapeutics 02/2022 - 08/2003
8	Biological Therapy 12/2021 - 05/2008
2	Contraindications 01/2022 - 07/2007
2	Phototherapy (Light Therapy) 01/2019 - 02/2017
1	Hair Removal (Depilation) 01/2022